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Summary 
Parkinson disease (PD) is a common neurodegenerative movement disorder that increases in 
prevalence with age. It is characterized clinically by resting tremor, rigidity, bradykinesia, and 
failing balance, and is due to the gradual loss of the dopaminergic neurons in the substantia nigra 
of the midbrain. Different factors including environmental (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), 6-hydroxydopamine (6-OHDA), etc.) and genetic (PINK1, DJ1 and 
LRRK2) have been found to cause the loss of the dopaminergic neurons in the substantia nigra. 
In addition, deficiency of respiratory chain complexes (complex I, II and IV) and increased 
levels of mtDNA deletions have been identified in PD patients. All of these factors, from the 
environmental to the genetic and the biochemical converge on one site, namely the 
mitochondrion: MPTP poisons complex I of the respiratory chain, PINK1, DJ1 and LRRK2 have 
all been linked to mitochondrial and lastly, mutations in the catalytic subunit of the 
mitochondrial DNA polymerase, POLG1, are known to cause Parkinsonism.  
The POLG1 gene also contains a trinucleotide (CAG) repeat region and while the majority of 
individuals have 10 CAG repeats (10Q) this region is also unstable and both longer and shorter 
repeats are seen. Previous studies have highlighted an association between CAG length in 
POLG1 and the development of PD. This has been done in different population such as England 
and United states, also for Nordic population (Finland and Sweden). In most populations studied, 
an association has been found, but in one population (England) no association was seen. The aim 
of this study was, therefore, to ascertain whether the length polymorphism of the CAG tract in 
POLG1 was associated with PD in the Norwegian population. In order to do this we studied 
cohort of Norwegian patients and age-matched controls that had been collected and clinically 
characterized as part of the ParkVest study.   
We found a significant association between the non 10Q alleles (P= 0.027; OR 1.53), especially 
12Q (P= 0.031; OR 2.38), and PD. In addition, meta-analysis of all available studies confirmed a 
highly significant association between the non 10Q alleles (P= 0.0004; OR 1.27) particularly 
12Q (P= 0.0047; OR 1.55) and PD. This pooled analysis also showed significant association 
between 9Q and PD (P= 0.0427; OR 1.21). Our results suggest that CAG repeat polymorphism 
in the POLG1 can be a risk factor or marker for PD. 
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1. Introduction 
1.1 Mitochondria 
1.1.1 History and Origin 
Mitochondria originated between 3.45 and 2 billion years ago from an endosymbiotic 
relationship between an α-proteobacterial organism and an anaerobic host cell. Mitochondria are 
known as the “power houses” of the cell due to their ability to produce energy in the form of 
adenosine triphosphate (ATP) from carbohydrates and fat by the oxidative phosphorylation 
(OXPHOS) process. Aerobic bacteria would have provided an aerobic cell which can carry out 
oxidative metabolism by proteins that encode in α-proteobacterial genome (1). 
Rickettsia prowazekii, an intracellular parasite, has a similar genome to mtDNA and is possibly 
related to the mitochondrial ancestor. Most of the original mitochondrial genes have been 
translocated to the nucleus during evolution and today only 13 peptide genes are still encoded in 
mtDNA (2, 3).  
1.1.2 Structure 
Mitochondria appear as round or oval-shaped structures under the electron-microscope (figure 
1). In reality, they form a dynamic network or reticulum undergoing continuous fusion and 
fission (4). Mitochondria are bilayer organelles consisting of an inner space called matrix space, 
an outer membrane (OM) and an inner membrane (IM) with a space in between that is called the 
intermembrane space (IMS) and the space surrounded by the inner membrane is the matrix 
which contains a high number of enzymes (proteins), RNAs and mitochondrial DNA and is 
segmented by segments that extend from the inner membrane called cristae (4). 
The outer membrane plays a role as the barrier and encloses the mitochondrion. It has porins and 
non-selective membrane channels formed by integral membrane proteins (5). Unlike the outer 
membrane there is no porin in the inner membrane and it is a highly impermeable layer. Ions and 
molecules are transported through this layer by the help of different transporters (carrier 
molecules). Proteins responsible for the redox reactions of oxidative phosphorylation and ATP 
synthase (the respiratory chain) that generates ATP in the matrix are present in this inner 
membrane. The mitochondrial inner membrane contains a high amount of  
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protein (75 %) compared to other membrane-bound organelles (usually 50 % protein and 50 % 
lipid) (1). The amount of inner mitochondrial membrane per cell depends on the bioenergetic 
parameters (energy requirements of the cell) in the cell which can change the size of 
mitochondria instead of increasing the number of mitochondria in the cell (6, 7). The number of 
mitochondria in each cell is variable and can reach into several thousand in high energy 
demanding tissues like neuronal tissue, cardiac muscle etc., and the number of mtDNA in each 
mitochondrion varies between 2-10 (8). 
1.1.3 Function 
Mitochondria are involved in variety functions including fatty acid metabolism, urea cycle, heme 
biosynthesis and lipid biosynthesis and metabolism (9). The focus of this thesis is on one of the 
most important functions of mitochondria which is converting the energy in different metabolic 
fuels such as glucose, to the chemical bound energy in ATP molecules which supplies of the 
energy in most biological reactions.  
Glucose is one of the major sources of energy and is broken down by glycolysis into pyruvate. 
Glycolysis occurs in the cytosol and its end product, pyruvate, must be transported into 
mitochondria where it is converted to acetyl CoA that then enters the citric acid cycle (Krebs 
cycle). Acetyl coA is further metabolized by the Krebs cycle to produce carbon dioxide and 
water and during this process, cofactors are reduced (NAD
+
 to NADH and FAD to FADH2).  
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NADH and FADH2 are electron carriers and during oxidative phosphorylation, which takes place 
in the inner membrane of mitochondria, electrons are donated from NADH and FADH2 to either 
complex I or II of the respiratory chain. The process of electron transport from one complex to 
another is associated with the release of energy and synthesis of ATP from ADP (1). The 
electron transport chain consists a number of different protein complexes (figure 2), Complex I 
(NADH: ubiquinone oxidoreductase), Complex II or succinate dehydrogenase, Complex III or 
cytochrome bc1 complex, Complex IV and Complex V. Complex V or H
+–ATP synthase is the 
last complex in respiratory chain which is activated by H
+
 flow from innermembrane into the 
matrix resulting in ATP synthesis from ADP and Pi.  
1.1.4 Genome 
Mitochondria have their own 16.5 (kb) circular double-stranded DNA genome which is 
composed of 37 genes comprising 13 peptides, 22 tRNAs and 2 rRNAs (figure 3). Mitochondrial 
DNA does not have any introns, but there is a non-coding region which is known as the “D-loop” 
and is the site for the origin of replication and the promoters for transcription. The peptides 
which are encoded by mtDNA are subunits of the respiratory chain complexes I (ND1-ND6, 
ND4L), III (CYB), IV (COX I-IV) and V (ATPase 6, ATPase 8). Complex II is encoded 
exclusively in the nucleus. All other proteins such as the other components of the respiratory 
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chain, different enzymes, chaperones (protein) and replication machinery, including Pol γ (DNA 
polymerase gamma) are encoded by nuclear genome (10, 11). 
)
 
1.1.5 Replication and inheritance 
Mitochondria are inherited exclusively from the mother, which makes it possible to use mtDNA 
in order to trace the maternal ancestry of populations (13). There are two models for mtDNA 
replication, the asynchronous strand displacement model and the strand coupled model. In 
asynchronous strand displacement model, replication of the heavy strand starts prior to 
replication of the light strand and there is a gap between replication start times of these two 
strands. In strand couple model both strand of mtDNA replicate simultaneously from replication 
zone. Mitochondria in human cells use both model to replicate its own DNA (10).  
1.1.6 DNA polymerase gamma (DNA polymerase γ) 
Polymerase gamma (Pol γ) is a DNA dependent, DNA polymerase consisting of a catalytic 
subunit (140 kDa) and accessory subunit (55 kDa)Human Pol γ is in fact a heterotrimer that is 
composed of one catalytic subunit that binds two accessory subunits. Accessory subunit 
functions include -increasing DNA binding affinity and primer recognition which is important in 
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the initiation of replication and increasing the holoenzyme structural integrity (14, 15). 
Exonuclease and DNA polymerase activity are the most important functions of Pol γ and these 
functions reside in the catalytic subunit. The accessory subunit is encoded by the POLG2 gene 
on chromosome 17q23-24 and catalytic subunit by POLG1 gene on chromosome 15q25. The 
catalytic subunit consists of an exonuclease domain, a polymerase domain, and a linker region 
which is involved in DNA binding and interaction with the accessory subunits (figure 4) (16, 
17). The Pol γ pre-protein has 1239 amino acids which is encoded by 23 exon and the 
mitochondrial signal is at the N-terminal of the POLG pre-protein which is cleaved off after 
translocation to the mitochondria (18). Pol γ repair function is mostly limited to base excision 
repair (BER) which use two pathways; single-nucleotide-BER (SN-BER) or long-patch BER 
(LP-BER) (19).  
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1.1.7 Human Pol γ mutation 
POLG1 point mutations are associated with a wide spectrum of disease (20).Point mutations in 
the POLG1 gene can eliminate the polymerase or proofreading activity and lead to secondary 
defects in mtDNA during replication. This in turn, can cause of dysfunction of the respiratory 
chain. Almost 150 mutations in POLG1 are listed by The Human Pol γ Mutation Database 
(http://tools.niehs.nih.gov/POLG/). Mutations in POLG1 are spread through all domains (figure 
5) and most of these mutations were found in patients with mitochondrial disease. Different 
mutations in POLG1 allele in patients with mitochondrial disease can take place, which show 
strong evidence of contribution POLG1 mutations to brain and liver damage in infants (Alpers 
syndrome) and neuromuscular tissues in adults (PEO) (19).   
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1.1.8 Dysfunction and disease in associated with POLG1 
POLG1 mutations are a common cause of mitochondrial disease and more than 150 pathogenic 
POLG1 mutations have been reported (21). Autosomal dominant progressive external 
ophthalmoplegia (PEO) was the first disorder to be described, which was caused by mutations in 
POLG1 (22).POLG1 mutations cause a variety of clinical syndromes including autosomal 
recessive and dominant PEO (23), Alpers-Huttenlocher syndrome (24) and mitochondrial 
spinocerebellar ataxia and epilepsy (MSCAE) (25). 
 
1.2 Parkinson's disease 
Parkinson disease (PD) was first described in 1817 by James Parkinson in his paper “An essay 
on shaking palsy” (26). PD is a relatively common neurodegenerative disorder with an age 
depended prevalence (108 to 257/100,000 in the general population; 1280 to 1500/100,000 in the 
over 60 years of age). The incidence of PD in Norwegian population is 12.6 per 100,000 
individuals and male-to-female ratio is 1.58 (Clinical onset of PD in women is 68.6 and 66.3 
years for men) (27). PD is characterized clinically by resting tremor, rigidity, bradykinesia, 
failing balance and a variety of non-motor symptoms including cognitive and behavioral changes 
and sleep disorder. The course is slowly progressive leading to increasing motor disability and 
shortened life expectancy. The pathophysiology of PD involves gradual loss of the dopaminergic 
neurons in the substantia nigra of the midbrain, resulting in decreased nigrostriatal input and 
ultimately decreased cortical motor activity resulting in the hypokinetic character of the disorder 
(28).  
1.2.1 Etiology of PD 
1.2.1.1 Environmental factors 
Several environmental factors are associated with PD. The compound methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) which is an inhibitor of the mitochondrial respiratory complex I  
selectively damages the dopaminergic neurons of the substantia nigra, presumably because it is 
specifically taken up by the dopamine reuptake receptors of the nigrostriatal terminals, and 
subsequently concentrated in mitochondria where it poisons complex I. 6-hydroxydopamine (6-
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OHDA) is another neurotoxin that induces oxidative stress and generates active oxygen species 
in the form of superoxide (O2). It is conjectured that the increase ROS production level in the 
mitochondria leads to mitochondrial alterations and induces apoptosis in dopaminergic neurons 
(29, 30). Interestingly, smoking cigarettes and drinking coffee are protective factors in PD (31).  
1.2.1.2 Genetic factors 
Most PD cases are sporadic and idiopathic, meaning that the etiology is unknown. However, in 
recent years several genes have been identified causing familial PD. 
1.2.1.2.1 Monogenic (Mendelian, familial) PD  
Recently, mutations in genes such as α-synuclein, Parkin, PINK1, DJ1 and LRRK2 have been 
identified causing PD (32, 33). Recent studies show a significant association between mutations 
in Parkin and α-synuclein and cellular ubiquitin proteasomal system (UPS) which leads to 
decreasing clearance of unwanted proteins (34). 
1.2.1.2.2 Genes in sporadic PD 
While the great majority of PD cases are sporadic (non-familial), and only few caused by single 
gene defects, there is increasing evidence that genetic risk factors play a major role in the 
pathogenesis of sporadic PD. Genetic association studies comparing large groups of PD patients 
with healthy controls have shown mutant glucocerebrosidase can be a risk factor for the 
development of PD (35). Moreover, haplotype analysis shows α-synuclein gene polymorphism is 
a risk factor for the development of parkinsonism (36). One problem with genetic association 
studies is that they do not always directly identify risk variants. These studies do not necessarily 
identify the genes which are associated with PD, but can be interpreted as markers for the disease 
base on linkage disequilibrium (LD). Thus, these markers might be near neighbors to the disease 
allele which carries a mutation gene (cis with marker) or a disease allele in adjacent gene (31).   
1.2.2 PD and Mitochondrial dysfunction 
There is increasing evidence suggesting that mitochondrial dysfunction plays a role in the 
etiology of PD (37-39). Deficiency of complex I was shown in post-mortem brains of PD 
patients (40, 41). Deficiency of the mitochondrial respiratory chain complexes I, II and IV were 
also demonstrated in skeletal muscle samples from living patients with Parkinson’s disease (42, 
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43). Other studies have shown more deletions in mtDNA in the brains of patients with PD 
compared to an age-matched control group (37). In addition, both PINK1 and Parkin are linked 
to mitochondria dynamics and function and it has been suggested that the association between 
mutations in these genes and PD is an increased oxidative stress and free radical damage (44, 
45). 
 
1.3 Trinucleotide repeats  
1.3.1 Biology of trinucleotide repeats 
Short tandem repeats (STR) of nucleotides such as mono-, di-, tri- or tetranucleotide repeats are 
usually classified as microsatellites. Even penta- or hexa- nucleotide repeats can be classified in 
this way (46). There is no minimum number of repeats or number of nucleotides for a tandem 
repeat to be referred to as a microsatellite. Almost 3% of genome comprises microsatellites 
meaning that there are more than one million microsatellite regions in the human genome. 
Moreover, the number of microsatellites increases at the ends of chromosomes. It seems there is 
a positive correlation between the size of genome and number of microsatellites and trinucleotide 
repeats have the lowest frequency compared to the other microsatellites (mono-, di-, tri- or 
tetranucleotide repeats) (46). 
One of the intrinsic characters of microsatellites is their high length mutability and this feature 
makes them a good genetic marker in different type of studies such as population genetics, 
genetic mapping and linkage analysis (47). Trinucleotide repeats (TNRs) are one the most 
important class of microsatellites, due to their known role in triplet repeat expansion diseases 
(TREDs). 
1.3.2 Trinucleotide repeat disorder 
Instability in TNRs is the cause of several developmental and neuromuscular disorders. 
Mismatch repair deficiency is one of the reasons for expanding triplet repeats (48) Instability of 
TNRs is reported in different human disorders, including Huntington’s disease (HD), myotonic 
dystrophy (DM), and several forms of spinocerebellar ataxia (eg SCA1) (49, 50). Nasir .et al. 
1996 showed that expansion of the polyglutamine tract in huntingtin protein can lead to a 
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conformational change causing altered protein mobility which is considerable issues for forming 
neural network during embryonic development and it causations of Huntington disease (51).  
1.3.3 trinucleotide repeats in POLG1 
The human POLG1 gene contains a unique feature that is absent in the mouse, drosophila or 
yeast: the human POLG1 gene has a trinucleotide (CAG) repeat in exon 2 in the NH2-terminal 
domain of the gene. According to the NCBI Reference sequence (NG_008218.1) it contains 10 
glutamine-encoding CAG codons, followed by a single CAA and two further CAGs (52).   
Analysis of CAG trinucleotide repeats in POLG1 in genomic DNA from single-cell clones (such 
as LS180, LS174T, AN3CA, etc.) showed this region of POLG1 is unstable. Finding of different 
POLG1 polymorphisms in one single-cell clone indicate expansion or contraction of the CAG 
repeat sequence. Also, the presence or intensity of each allele was varied from clone to clone. 
However in some clones such as SKUT-1 and DU145 the stability of CAG trinucleotide repeats 
region is reported (53).  
Interestingly, recombinant POLG1 with ΔQ10 (10 CAG repeat deleted) was completely stable in 
human cells and there was no changes in proofreading activity and mitochondrial function 
(oxygen consumption), however polymerase activity and Pol γ expression slightly increased and 
mtDNA content slightly decreased in compare to normal cell line in Spelbrink et al. 2000 study 
(18) 
1.3.4 POLG1 trinucleotide repeats and diseases 
The investigation of unstable TNRs region in exonic part of POLG1 was surprising because of 
the prominent function and sensitivity of this enzyme in mitochondrial biogenesis. Several 
studies tried to find about the possible association between instability of this trinucleotide repeats 
and different disease. Different studies suggest an association between the length of the CAG 
repeat in POLG1 gene and breast cancer (54), testicular cancer (55, 56) and male infertility (57). 
The findings are inconsistent however, as other studies do not confirm these associations (58-
62).  
Different studies from Sweden (63), Finland (64) and United states (65) reported an association 
between the length alteration of CAG trinucleotide repeats and PD. These studies reported 
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significant association between non 10 repeats of CAG trinucleotide repeats and PD. However 
three different studies for England population (66-68) do not confirm these associations.  
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2. Aims of the study  
Given the mounting evidence that mitochondrial dysfunction plays a role in PD together with 
early studies showing an association between non10/11Q tract lengths in other populations, the 
aim of this thesis was to investigate the possible association between the number of CAG repeats 
in POLG1 gene and Parkinson disease in the Norwegian population. The sub aims were: 
1. To investigate if the CAG repeat length was associated in idiopathic PD in Norwegian 
patients and if so whether this was specific for one of more length variants. 
2. Assess our data in association with all of the recorded data using meta-analysis. 
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3. Patients and materials  
3.1 Patients and Controls 
All patients in this study were Norwegian, with a mean age of 68.2 years and similar number of 
male and female. The controls were the patient’s spouse or one of their relatives that were 
neurologically healthy; controls had a mean age of 67.4 years. The study group consisted of 191 
patients with PD (mean age of 68.2 years) and 191 age-matched, healthy controls from the 
Norwegian ParkVest study, a prospective, population based study of incident PD in Western and 
Southern Norway. A detailed description of the ParkVest study design has been published (27).  
My clinical colleagues have ensured that the baseline examination including the Unified 
Parkinson Disease Rating Scale part II and III (subunits for Activities of Daily Living and motor 
symptoms) and the Hoehn and Yahr scale (HY) (69) was performed at the time of initial 
diagnosis with follow-up visits every half year. The motor subtype was defined as Postural 
Instability and Gait Difficulty (PIGD), indeterminate, or Tremor Dominant (TD) depending on 
the dominating motor symptom (70).Only individuals fulfilling clinical diagnostic criteria for PD 
(71) after at least 3 years follow-up were included (n=195) and of these sequencing results were 
obtained from 191. Controls were recruited from the patient’s spouses, friends and others. We 
excluded 1st and 2nd degree relatives of patients (n=10), one control person who developed 
clinical PD within the first three years of follow-up as well as those without valid sequencing 
results (n=2). After matching for age, the control group consisted of 191 individuals. 
3.2 Material 
   
Commercial Kits   
Article Catalogue No. Producer 
AmpliTaq Gold® DNA 
Polymerase 
4338856 Life Technologies, 
Invitrogen 
GeneAmp® 10X PCR Gold 
Buffer  
4338856 Life Technologies, 
Invitrogen 
25 mM MgCl2  4338856 Life Technologies, 
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Invitrogen 
2.5 mM dNTP Mix R725-01 Life Technologies, 
Invitrogen 
Betaine 070M6047  
BigDye® Terminator v1.1 
Cycle Sequencing Kit 
4336772 Life Technologies, 
Invitrogen 
GeneJET™ PCR Purification 
Kit  
#K0702 Fermentas GmbH 
QIAamp DNA Mini Kit  51306 QIAGEN  
Sequence Buffer 4336697 Life Technologies, 
Invitrogen 
   
Primers for PCR   
Target gene Primer sequence  
POLG1 Fw 5’ – GGT GGA AGG CAG GCA TGG TCA AA – 3’ 
 Rev 5’ – GCT GGT CCA GGT TGT CCC CGT AGA G – 3’ 
   
General chemicals and solutions  
Chemical/Solution Catalogue No. Supplier 
Ethidium Bromide (EtBr) E1510 Sigma-Aldrich, USA 
Seakem LE Agarose   
6X Orange DNA Loading 
Dye 
R0631 Thermo Fisher Scientific 
Inc 
GeneRuler™ 50 bp DNA 
Ladder, ready-to-use 
SM1133 Thermo Fisher Scientific 
Inc 
10X TBE solution Am9863 Life Technologies, 
Ambion 
   
Hardware   
Name Catalogue No./Model Supplier 
NanoPhotometerTM P-Class P 300 Implen GmbH, Germany 
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Thermal Cycler Veriti Applied Biosystems 
   
Software   
Program  Version Supplier 
Microsoft Office 2007 Microsoft Corporation , 
Redmond, USA 
Graphpad QuickCalc free web calculator GraphPad Software, Inc, 
CA 92037  USA 
SPSS 19 SPSS Inc., USA. 
Geneious 5 Biomatters Ltd, New 
Zealand 
 
3.3 Methods  
3.3.1 DNA extraction, amplification and sequencing 
DNA was extracted from frozen (-80C) whole blood using a commercial kit (QIAamp DNA 
Mini Kit, QIAGEN) according to the manufacturer’s protocol. DNA concentration and quality 
was determined using a Nano Photometer P300 spectrophotometer (Implen GmbH, Germany). 
The polymerase chain reaction (PCR) is a robust technique to amplify DNA in vitro (72).PCR 
comprises three stages: melting DNA to separate the double strands  (above 90°C), annealing of 
the primer (temperature depends on the primer sequence usually ~55°-68°C) and DNA synthesis: 
extension (depends on DNA polymerase enzyme 72°C). The PCR reactions were carried out 
using a Veriti thermal cycler (Applied Biosystems, USA). Total volume of each reaction was 25 
microliters (μl) and each reaction contained 1.5 mM MgCl2 (Invitrogen # 4338856), 0.8 mM 
dNTP (Invitrogen # R725-01), 1.50 M betain (Invitrogen # 070M6047), 0.6 unit (U) AmpliTaq 
polymerase ( Invitrogen # 4338856), 1x PCR-Gold buffer ( Invitrogen # 4338856), 0.6 micro 
molar (µM) of each primers (forward and reverse) and 100 nano gram (ng) genomic DNA as 
template. The combination of Milli-Q water and template varied according to concentration of 
the DNA for each sample, but each reaction were carried out in a total volume of 25 microliters 
(μl).  
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Total PCR cycles were 30 which each cycle consists of the DNA denaturation for 30 sec at 94 
°C, the primer annealing for 30 seconds at 58 °C and the elongation for 30 seconds at 72 °C.      
PCR products were run on 1% agarose gel containing ethidium bromide (0.5um/ml) at 40V for 
120min. Amplicon purification was done with GeneJET™ PCR Purification Kit (#K0702, 
Fermentas GmbH) according to the manufacturer’s protocol.  
3.3.2 Sanger Sequencing (Chain-termination methods) 
Sequencing was carried out with BigDye® Terminator v1.1 Cycle Sequencing Kit (ABI) in a 10 
µl reaction which contained 1 µl BigDye® Terminator v1.1 (ABI, cat# 4336772 ), 2 µl 
sequencing buffer (5X) (ABI, cat# 4336697), 0.5 µl primer (5 pmol), 2 µl betain (ABI, cat# 
070M6047) and 2 µl DNA template (1-10 ng). Sequence of all samples was performed using 
forward primer that was used in PCR except the samples with low quality of chromatogram 
which reversed primer used, too. The products were analyzed on an ABI 3100 automated DNA 
sequencer. 
Total PCR cycles for sequencing were 25 and each cycle consist of 10 sec DNA denaturation  at 
96 °C for , 5 seconds primer annealing at 50 °C and 4 minutes for elongation at 60 °C .   
3.3.3 Analyze sequences (Bioinformatics) 
Heterozygous POLG1 sequence data were analyzed with the Geneious software v5.1 
(http://www.geneious.com) and the NCBI sequence NM_002693.2 was used as a reference for 
POLG1. 
3.3.4 Statistical analysis 
To evaluate the differences in frequency of the genotypes between the patient and controls and 
find out any possible association between any specific allele and PD Fisher exact and chi-square 
test were applied. Fisher's exact test, always gives an exact P value and works fine with small 
sample sizes, so we used it for our result from Norwegian population to find out is there enough 
evidence to reject the null hypothesis which was “There is no association between length of 
CAG tract in POLG1 gene and Parkinson disease”; however the chi-square test gives the 
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appropriate result for large sample sizes. Chi-squared test was applied for meta-analysis to 
determine the difference of allele frequencies of POLG1 in combined PD and control group were 
significantly different and find the possible association between the frequencies of specific allele 
and PD. The p-value <0.05 was considered to indicate statistical significance. Odds ratio were 
estimated with 95 percent confidence intervals (CI 95%) in these studies. 
With the use of simple 2 x 2 tables we can quantify the relationship between exposure and 
disease with odds ratio (OR). General structure of a 2×2 table:  
General Structure of 2 × 2 table 
B 
(Disease) 
PD (+) Control (-) Totals 
A 
(Exposure) 
high exposure in 
PD group (+) 
a b a+b 
high exposure in 
control group (-) 
c d c+d 
Total a+c b+d N=a+b+c+d 
pA = (a+b)/NT 
pB = (a+c)/N 
 
Odds ratio formula based on 2×2 table: 
OR 
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4 Results  
4.1 Higher frequency of common POLG1 alleles in the control group compared to the 
PD group  
Table 1 shows the POLG1 allele frequency in patients and controls and table 2 shows the 
genotype frequencies. Figure 6 shows the allele distributions in control group and PD group
 
 
 
 
Table 2.  Genotype frequencies for POLG1. 382 samples in two groups (control and PD) 
analyzed. 10/10 was the most frequent genotype in both groups.   
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Irrespective of CAG repeat length, there was a higher proportion of heterozygous individuals in 
the PD group compared to the control group, however the control group had a higher number 
who were homozygous (see figure 7). In total (i.e. all 382 individuals), 66.5 % were homozygous 
(10/10 or 11/11) of which 65.2 % were 10/10 (59.2 % of the PD and 71.2 % of the control group) 
and 1.3 % were 11/11 (2.1 % of the PD group and 0.5 % of the control group). In contrast, 33.5 
% were heterozygous (38.7 % PD group and 28.3 % control group) with 93.8 % of the 
heterozygous s having one 10-repeat allele and a second allele with a repeat length of 8-16 (55.5 
% PD and 38.3 % Control group).  
The percentage of individuals who were heterozygous for their CAG repeats length was 
significantly higher in the PD group compared to control group (P= 0.0392; OR 1.25, 95% CI 
1.04 to 2.46). Three percent (3%) of the samples had no 10 CAG repeat allele (3.7% PD and 
2.6% Controls) and the only 4R variants were in the control group (one allele 3R (CAG) 10 and 
another one 4R (CAG) 9).  
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Analysis of DNA sequences from both groups (patients and controls) revealed that the ten-repeat 
allele (10Q) is the most common allele in the Norwegian population; the frequency of this allele 
in the control group (84.3 %) was higher than PD group (77.7 %). There was also a significant 
difference between numbers of non 10Q alleles in the PD group compared to control (P= 0.027; 
OR 1.53, 95% CI 1.06 to 2.21). The most common allele after 10Q was 11Q and this was true for 
both groups: in total, 20.4 % of all samples had one 11Q allele (22.5 % PD group and 18.3 % 
Control group) and 1.3 % were homozygous for 11Q (2.1 % PD group and 0.5% Control group). 
The frequency of both the 11Q and 12Q alleles was higher in PD group (11Q; 13.1 %, 12Q; 6.0 
%) than the control group (11Q; 10.5 %, 12Q; 2.6 %); however, the difference was significant 
only for the 12Q alleles in PD group and control group (P= 0.031; OR 2.38, 95% CI 1.11 to 
5.07). Two rare alleles, the 14Q and 16Q, were found in the control group and both individuals 
were heterozygotes with a 10Q on the other allele. There were no homozygotes for rare alleles 
(8, 9, 12, 13, 14 and 16Q) in our samples. 
Based on the Hardy-Weinberg equation, it can be predicted that 10/10 alleles should occur in 
approximately 66 % of individuals in whole population (patient and control groups). In our 
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study, we found 65.2 % carried the 10/10 genotype, which approximates well to the prediction. 
Looking at other allele combinations, we found that 10/X (X is any allele except 10) was 33.2 % 
as opposed to 30.6 % predicted, and for X/X we found 3.1% versus 3.6 % predicted. 
4.2  Meta-analysis: Non-10Q alleles correlate with PD 
In this pooled study we used all available previous studies that had investigated the association 
between CAG trinucleotide repeat length in the POLG1 and Parkinson disease (16, 63, 65, 67, 
68, 73). Figure 8 shows the distribution of alleles of the combined control and PD groups. All of 
these studies had three criteria: 1) Control subjects were neurologically healthy individuals; 2) 
The patients were diagnosed as idiopathic PD; 3) Number of CAG repeat in each allele among 
the cases and the controls reported. In total there were 1597 patients with a mean age of 69.2 and 
1493 controls with a mean age of 67.4. The populations were from England, Sweden, Finland, 
United States and Norway. (Table 1. in supplementary data) 
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Poly-Q 
combined 
PD 
combined 
PD % 
combined 
Control  
combined 
Control % 
Total Total % 
5Q 0 0.00 1 0.03 1 0.0% 
6Q 2 0.06 4 0.12 6 0.1% 
7Q 21 0.66 7 0.21 28 0.4% 
8Q 15 0.47 11 0.33 26 0.4% 
9Q 71 2.22 52 1.54 123 1.9% 
4R+9Q 7 0.22 3 0.09 10 0.2% 
10Q 2629 82.31 2881 85.54 5510 84.0% 
11Q 338 10.58 326 9.68 664 10.1% 
12Q 102 3.19 70 2.08 172 2.6% 
13Q 8 0.25 7 0.21 15 0.2% 
14Q 1 0.03 3 0.09 4 0.1% 
15Q 0 0.00 2 0.06 2 0.0% 
16Q 0 0.00 1 0.03 1 0.0% 
Total 3194 
 
3368 
 
6562 
 
Table 3. Frequencies of POLG1 alleles in meta-analysis. POLG1 allele frequencies in a mixed group of control 
and PD samples compromised of 7 studies. 
Once again, the most common allele in both control and PD group was 10Q (PD; 82.31 %, 
control; 85.54 %). The frequency of the 10Q is lower in the PD group than control group, 
however, the frequency of non 10Q allele (7, 8, 9, 11, 12,13Q) was higher in the PD group than 
controls (see table 3). There was also a significant association between non 10Q alleles (≠10Q) 
and PD (χ2=12.70, 1 df, P= 0.0004; OR 1.27, 95% CI 1.11 to 1.45). The second commonest 
allele in both groups was 11Q (PD; 10.58 %, control; 9.68 %). The frequency of the 11Q and 
12Q allele in PD group (11Q; 10.58 %, 12Q; 3.19 %) was higher than control group (11Q; 9.68 
%, 12Q; 2.08 %) and there was significant association between 12Q of CAG and PD (χ2=7.98, 1 
df, P= 0.0047; OR 1.55, 95% CI 1.14 to 2.11). 
9Q that had high frequency in PD group (2.22 %) compared to control group (1.54 %) which the 
difference was significant according to Chi-square test (χ2=4.109, 1 df, P= 0.0427; OR 1.21, 
95% CI 1.01 to 2.08). 
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Odds ratio calculated for each study with 95% confidence intervals (95% CI) to estimate 
probability of increasing risk of PD in persons with non 10Q allele (figure 9). In conclusion 
overall odds ratio was OR=1.21 (95% CI) which was lower than our study for Norwegian 
population (OR=1.53, 95 CI).     
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5 Discussion 
5.1 The main experimental findings 
The main findings of this study were: 
 The most common allele in both the control and PD groups was the 10Q. 
 11Q was the second most frequent allele in both groups. 
 A high frequency of heterozygosity (10/X) in the PD group compared to the controls. 
 A high frequency of homozygosity (10/10 and 11/11) in the control group compared to 
patients with PD. 
 A high frequency of non 10Q alleles in PD group, especially 12Q. 
 A significant association between non 10Q (P=0.027) and Parkinson disease. 
 A significant association between 12Q (P=0.031) and Parkinson disease. 
 The most common alleles in the meta-analysis of controls and PD patients were 10Q 
followed by 11Q. 
 Meta-analysis also showed a significant association between 9Q (P=0.0427), 12Q 
(P=0.0047) and all non 10Q (P= 0.0004) alleles and Parkinson disease. 
 
In order to investigate the possible role of the CAG repeat length variation at POLG1 gene in 
Parkinson disease we have studied repeat length variation at this locus in both patients with PD 
and age-matched controls. All individuals were Norwegians and there similar number of both 
genders. Also In addition we performed a meta-analysis of all previously published results that 
have looked at CAG length polymorphism in the POLG1 gene and PD (6 published articles until 
2010). A total of 1597 PD cases and 1493 controls were found. 
5.2 The biology of the CAG repeat in POLG1 
Our results show that 10Q is the most common allele both in the Norwegian population (81 %) 
and the pooled analysis (84 %). Interestingly, this is species specific Gorilla is similar to human 
with 10Q being the commonest, but in chimpanzees it is 7Q and bonobos 5Q. Some species such 
as the mouse and drosophila lack a CAG tract in POLG1 altogether (74). Several studies showed 
that 10Q allele is the most common allele in general population of humans (58, 59, 64, 65). The 
next most common allele in our and all previous studies was 11Q; together the 10Q and 11Q 
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alleles comprised over 90 % in our study (92.8 %) and the pooled analysis (95.22%). This 
appears to be an evolutionary conserved principle: primate species have one common allele for 
POLG1 and the next common allele in each of these species has one more  glutamine and these 
two alleles (most common allele and the second most common allele which has one more amino 
acid) comprised more than 90 % of allele frequencies (74).  
The finding of a range of TNR in a specific gene in general population appears to be a normal 
phenomenon. The range can vary and can be large (11-34 TNR in the Huntington's disease gene 
or 6-39 in SCA, etc. (75)). The range in POLG1 appears much narrower with 10 CAG repeats 
being by far the most prevalent allele in general population irrespective of whether they had PD 
or not. The range of CAG repeats in POLG1 can vary between 5Q to 16Q, but given the 
predominance of the 10Q (or 11Q), it is possible that optimal Polγ functions depends a specific 
number of glutamine amino acid and that variations of this number can lead to variation in Polγ 
function.  Impairment of Polγ function can potentially cause several problems for mitochondria 
including deletions of mtDNA and mtDNA depletion. These in turn can lead to respiratory chain 
deficiency. Indeed abnormal respiratory chain function has been demonstrated in PD patient’s 
brain at autopsy (39, 43) as have mtDNA deletions.  
The only non 10Q that we found in the homozygous state in our study was 11/11 (2.1 % PD 
group and 0.5 % Control group) and this also showed a higher frequency in PD group compared 
controls. The lack of homozygous non 10 or 11Q generally, and higher frequency of the only non 
10Q homozygous in PD group, suggest that allele length might indeed be important for optimal 
Polγ performance.  
5.3 Lack of the common 10Q allele in POLG1 is associated with PD 
In this study, we classified the 10Q allele as the common allele and all the other alleles were 
grouped as rare alleles. In some other studies, 10Q and 11Q alleles were grouped together for 
statistical analysis. We did not do this. We found a significant association between non 10 
CAG repeat lengths and Parkinson diseases, confirming the previous studies in Finland, 
Sweden and the United States (16, 63, 65).  Of the non-10/11Q variants, the strongest association 
was found with 12Q and this is also confirmed by our meta-analysis. Another allele with a 
significant association with PD in the pooled analysis was 9Q. However, we did not find any 
significant association between 9Q and PD in our study, probably because of the sample size. 
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The 9Q was, however, the most frequent allele after 12 Q in the PD group and this was true for 
the other studies, although not the Finnish, in which 9Q was more frequent than 12Q. The 
Finnish population is characterized by isolated communities and low genetic diversity population 
which perhaps explains the difference between Finland’s study and other studies (76). 
The absence of an association between non 10Q and PD in the three studies from the UK may 
have different explanations. A small sample size is one [7]. In this study, the PD group consisted 
of 22 patients and 31 controls (73). In another, 140 cases of PD and 90 controls were studied 
(67)). In the study by Tiangyou, the samples were not matched for age and sex. Another 
important confounding factor is ethnicity; this is potential problem in the Finnish study (16) due 
to the low genetic diversity. Since the association between non 10Q and PD has been confirmed 
by several different studies in Nordic countries, the question arises of whether this is specific to 
these populations. However, the finding of an association between non 10Q and PD in the study 
from USA that investigated a mixed Caucasian control group would tend to refute this (65). 
Lastly, it is important to remember that technical problems may also play a role. For example, 
the fragment analysis that was used in the study by Anvret et al., 2010 cannot recognize a 
9Q+1R (rs28567406) allele or any other possible sequence variation. 
The observed homozygosity values (10/10 and non 10/non10) are close to equilibrium values 
predicted by the Hardy Weinberg equation. However, there was a slight difference between the 
Hardy–Weinberg predication for heterozygosity (10/X) in our study (prediction 30.6 %, our 
study 33.2 %), although this deviation was not statistically significant. These result shows that 
locus is not an interesting locus for evolutionary evaluation, and that the general population is at 
equilibrium. (Allele frequencies of 10 and X do not change from one generation to another) 
5.4 Possible somatic instability of CAG repeats in POLG1 gene 
Existing studies of the CAG polymorphism in POLG1 gene have usually compared the 
frequency of these variants in blood samples from controls and PD patients. Only one study 
(Taanman et al. 2005) studied CAG polymorphism in 6 post-mortem brains. On the basis of 
other CAG repeat disorders, somatic instability of the POLG1 CAG length polymorphism in 
different tissues should also be considered. Gametic and somatic mosaicism of CAG repeat in 
the SCA1 gene was shown by isolated single cell study looking at sperm, blood and brain tissue 
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of spinocerebellar ataxia type 1 patients (77). These studies showed shorter CAG repeats in the 
cerebellum, which has a lower rate of cell division during neuronal network development, and 
longer CAG repeat in other parts of the brain suggesting that differences in early mitotic activity 
may result in tissue and cell specific segregation of different CAG repeat lengths (77). Hashida et 
al. 2001 showed heterogeneity of CAG repeat expansion in Purkinje and cerebellar granule cells 
in late onset dentatorubral-pallidoluysian atrophy (DRPLA) patients. Their study also showed 
higher CAG repeat heterogeneity in glial cells. Mitotic rate of cell division can be a possible 
explanation for such a difference (78). The neuronal population is controlled by apoptosis of 
damaged neurons during neuronal network development, which may explain the survival of 
neurons with lower expansion and the finding of neurons with lower expansion in homogenized 
tissue (78). Extension of CAG repeat length in POLG1 during mitotic division, especially during 
embryonic development by whatever mechanism (49) could lead to somatic mosaicism. This 
would make it difficult to assess the real proportion of existing alleles in tissues such as brain 
using conventional methods. According to these data, whole blood may not be a good tissue to 
analysis CAG length and any possible association with disease. In addition, any increase in the 
level of somatic mosaicism of POLG1 polymorphism heterogeneity during the human lifespan 
raises the possibility of finding the CAG repeat with longer length. At present, however, there is 
no evidence of either somatic differences of POLG1 CAG length or changes with time.     
5.5 Function of CAG repeat in POLG1 gene and Pol γ 
In silico analysis of RNA-folding shows that there is a 4.8% increase in required folding energy 
for variants with more than 10/11Q. The difference between the minimum free energy structure 
of the 10/11Q and non 10/11Q sequences may give different secondary structures of mRNA and 
differing stability (63).  Interestingly, Spelbrink et al. reported that POLG1 expression is 
modestly up-regulated in vitro by removing the CAG repeat segment (modified POLG1 by 
deletion 10 CAG repeats of POLG1 gene in in cultured HEK293T cells). In addition, their study 
indicated that there is no difference in enzymatic activity of modified POLG1. However, this 
study did not elaborate how the CAG tract may modulate POLG1 expression or enzymatic 
activity (18). This experiment indicated CAG repeats in POLG1 gene can regulate the expression 
of Pol γ; however the functional effect of the CAG tract length polymorphism remains unclear. 
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Kozlowski et al., 2010 showed a significant association between TNRs and the regulation of 
gene expression, transcription, DNA binding and transcription regulator activity in a functional 
association analysis (47). These data offer a potential explanation for the result of Spelbrink’s 
study which showed that loss of the CAG tract was associated with alteration of POLG1 
expression in vitro. These all data together suggest that the CAG TNR in POLG1 may have a 
regulatory function for expression of POLG1.  
Butland et al., 2007 also showed a positive correlation between the length of the CAG TNR and 
the level of polymorphism. They indicated that genes with uninterrupted CAG repeats of 10 or 
longer can potentially expand and become be a candidate gene for polyglutamine expansion 
disorders (79). However the study by Alba et al, 2001 suggested that CAG tracts interrupted by a 
CAA are more stable compared to uninterrupted tracts of equal length. The POLG1 CAG repeat 
is normally followed by CAA and perhaps this is why the 10Q allele is so prevalent in the 
normal population (80).  
Another important factor concerning the POLG1 CAG repeats, is the location of this TNR. The 
polyglutamine tract comes just after the mitochondrial import signal (81). Polymerase γ is 
translocated into the matrix of mitochondria by passing through the TOM40 complex (the 
translocase complex of the outer mitochondrial membrane) and TIM23 complex (the translocase 
complex of the inner mitochondrial membrane) (82). The importance of the CAG repeat region 
in POLG1 and its role in protein binding or protein interaction are unknown, but are potential 
sites of dysfunction. For example, expansion of this region might disrupt interaction between 
chaperon and import signal. Nasir .et al. 1996 showed that expansion of the polyglutamine tract 
in Huntingtin can lead to a conformational change causing altered protein mobility. In tissues 
such as brain and nerve cells which have a high energy demand any alteration in protein 
conformation which affects the Polγ translocation could potentially affect mitochondria 
biogenesis leading to decreased numbers of mitochondria or mtDNA depletion.  
5.6 Role of POLG1 polymorphism in mtDNA deletion and causation of PD  
The prevalence of PD increases with age over 50 years and it is significantly higher between 65 
and 90 years (83). There are several studies which have shown that mtDNA deletions increase 
during human lifespan in both muscle and neurons. The mechanisms that keep the balance 
36 | P a g e  
 
between the number of normal and deleted mtDNAs during a lifetime have yet to be identified 
(84), but this balance is more pronounced in tissues such brain and muscle probably due to their 
lack of regenerative capacity. There is evidence that mtDNA deletions accumulate during the 
human lifespan (84) and that PD patients accumulate deletions of mtDNA in the substantia nigra 
(85). In silico and in vitro studies suggest that altering CAG length in POLG1 can influence the 
mRNA stability and expression of POLG1. This could in turn affect Pol γ function. Thus it is 
appropriate to speculate that a dysfunctional Polγ can potentially affect aged nerve cells more 
than other tissues in this age range and lead them to lose more mtDNA. This can cause 
respiratory chain deficiency and lead the cell to death.         
5.7 POLG polymorphism can be a genetic marker  
Linkage and association should not be confused with one another. Two genetic loci are linked if 
they are inherited from parents to offspring more often by the chance and these two genetic loci 
are in linkage disequilibrium (LD) if they are found together on the same haplotype in population 
is greater than expected by chance (86). In fact, Linkage disequilibrium shows the nonrandom 
association between alleles at different loci (87). LD gives us information about past events and 
causes of gene-frequency in population such as natural selection during the time, gene 
conversion and mutation (88). LD study showed the relation between CAG and GGC 
microsatellites in Androgen Receptor gene (89).  
Genome Wide Association Studies (GWAS) have not shown an association between 
chromosome 15 (where POLG1 is located) and Parkinson’s disease (90). This does not exclude 
however a possible role for POLG sequence variation in PD as GWAS studies are generally less 
sensitive for rare variants. (91). Also, POLG1 haplotype analysis indicated six POLG haplotypes 
which there were not significant association between them and PD, however 9Q-CCAG 
haplotype had higher frequency among the PD group to compare with spouse controls (4.9% vs. 
1.3%). The small size of the samples can be the reason for non-significant association, but still 
their finding support our result from meta-analysis (31).   
Alternatively, it is possible that allelic variation of POLG1 itself does not influence PD, but acts 
as a marker for other, nearby localized genetic variants which increase susceptibility for PD and 
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are present in linkage disequilibrium with one or more of non-10/11Q alleles in certain 
populations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
38 | P a g e  
 
6. Conclusion 
Our study showed that non10 repeats in the POLG1 gene were more frequent in PD patients than 
in healthy population. This was especially true for the 12Q repeat. We also found the converse, 
that 10Q was significantly associated with control individuals. The 9Q allele, another 
polymorphism in the POLG gene, was significantly associated with PD in the pooled analysis 
but this was not confirmed in our study. Our data confirms previous studies and suggests that 
there is an association between CAG length polymorphism on the POLG gene and PD.  
The role of the CAG repeats in POLG1 gene is still unclear, but we speculate on the basis of in 
silico and in vitro studies, that altering CAG length affects Pol γ activity, which can lead to 
failure of the enzyme to properly replicate mtDNA and can therefore generate mtDNA deletion 
or depletion. If however, non 10Q repeats, particularly 12Q repeats are simply a marker for 
Parkinson disease the mechanism(s) underlying this association remain obscure. 
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7. Future perspectives 
In the future, further studies on polymorphic CAG repeat in POLG1 in other geographical 
regions and with powerful molecular methods such as X-ray crystallography, single cell studies, 
in vitro studies and Genome Wide Association study (GWAS) may help to find the possible role 
of POLG1 polymorphism in the CAG region in mitochondrial dysfunction and Parkinson 
disease. 
There are several parameters involved in mRNA stability and functions prediction by 
bioinformatics software which makes a complicated process with complex results that 
explanation of these result needs expertise. One of the criteria of mRNA prediction is Folding 
Free Energy (ΔG) to find out which conformation of mRNA is stable or has higher chance to be 
in the environment. Mfold web server (92) is well-known program to estimate the folding free 
energy (ΔG) for mRNA.  Anvret et al., 2010 showed the Folding Free Energy difference between 
the 10Q and non 10Q, so this time we used this program to find out the difference between 
folding free energy in 10Q allele and 12Q allele ((ΔG10- ΔG12)= 0.12%) (Figure 1, 
supplementary data) which showed slightly difference, although this program has good algorithm 
to predict second structure for small RNA such as tRNAs and rRNAs, but the performance of 
this program decrease with size of the RNAs (93), so the real difference can be higher than this. 
Second structure prediction for POLG protein was the other important feature that we looked at 
to find any possible difference between POLG polymorphism (performed by CLC Main 
Workbench 6.6.2, CLC Bio). There was no difference between 10Q and 11Q, but one β sheet 
elicited from Pol γ with 12Q. These finding can be an explanation for finding high frequencies of 
12Q allele in patients group (Table 2, supplementary data).   
 Using single cell studies to investigate somatic instability of CAG repeat in POLG1 gene in 
different cell types and different tissue with different age onset which can be useful to 
understand the possible expansion of POLG gene during lifespan and shows possible link 
between POLG polymorphism and mitochondria dysfunction in substantia nigra.    
Modified POLG gene and cloning methods such as study of Spelbrink et al 2000 for assessing or 
predicting the effects of CAG length in POLG gene expression and Pol γ function, could be 
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investigated in vitro to able us  find out the other property of the CAG repeat polymorphism 
function. 
Further investigations including association studies in other and larger populations can help us to 
find out the possible relation between CAG repeats in POLG1 and other mutation in POLG gene 
or possible linkage disequilibrium with the other gene or mutations on the other neighbor genes. 
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9. Appendix 
9.1 Supplementary data 
Table 1. Criteria of each study in Meta-analysis 
 
Ref cohort 
associati
on 
Case 
Case's 
Gender 
Case's 
mean 
age 
Ctrl 
Contr
ol's 
Gend
er 
Ctrl's 
mean 
age 
Origin 
England (68) - No 220 matched 71.41 157 
match
ed 
69.69 
British 
(Caucasian) 
England (67) 
UK 
cohort 
No 140 61.4% male 70.97 90 
36.7% 
male 
69.19 
British 
(Caucasian) 
Italian 
cohort 
No 279 60.5% male 47 285 
37.8% 
male 
62 
British 
(Caucasian) 
England (66) - No 22 matched 74 31 
match
ed 
71.6 
British 
(Caucasian) 
USA (65) 
Mixed 
Caucasian 
Ctrl 
Yes - n.a. n.a. 605 n.a. n.a. 
mixed 
Caucasian 
Main 
group 
Yes 641 56% male 65.3 292 
49% 
male 
68.2 
North 
American 
Caucasian 
Finland (64) 
Main 
group 
yes 140 83 Men 67.2 127 
47 
men 
65.8 
Finnish 
(Caucasian) 
unselecte
d Ctrl 
yes - n.a. n.a. 516 n.a. >85 
Finnish 
(Caucasian) 
OND Ctrl No - n.a. n.a. 120 n.a. n.a. 
Finnish 
(Caucasian) 
Sweden (63) - Yes 243 n.a. 67.3 279 n.a. 59.9 
Swedish 
(Caucasian) 
Norway 2012 - Yes 191 matched 68.2 191 
match
ed 
67.5 Caucasian 
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